ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
Aug 10, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?
The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study showed that finerenone reduces kidney and cardiovascular complications in patients with CKD and type 2 diabetes. In addition, the results demonstrated consistency independent of insulin use at baseline, and this area is the main focus of this subgroup analysis. The purpose of this analysis is to determine the amount of influence that insulin use has on kidney and cardiovascular outcomes and safety....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.